# KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

> **NCT06342960** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kyverna Therapeutics** · enrollment: 2 (actual)

## Conditions studied

- Lupus Nephritis
- Lupus Nephritis - WHO Class III
- Lupus Nephritis - WHO Class IV

## Interventions

- **BIOLOGICAL:** KYV-101 anti-CD19 CAR-T cell therapy
- **DRUG:** Standard lymphodepletion regimen

## Key facts

- **NCT ID:** NCT06342960
- **Lead sponsor:** Kyverna Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2028-10
- **Final completion:** 2029-01
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2025-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06342960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06342960, "KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06342960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*